Drug Trial Radar · NCT03848793
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
Last checked: Nov 20, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Mar 6, 2019
Primary completion
Jun 4, 2020
Study completion Dec 14, 2020
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.
Conditions
- Diabetes Mellitus, Type 2
Interventions
HS-20004Drug
treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: 16 weeks treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.